Welcome to AF Association®
Working to provide information, support and access to established, new or innovative treatments for Atrial Fibrillation (AF).
Edoxaban (Lixiana) is recommended as an option for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation who have one or more risk factors, such as:
- heart failure, high blood pressure or diabetes
- had a stroke or transient ischaemic attack before
- aged 75 years or older.
To read in full please click here
For more information on Edoxaban please read, download and print our NEW Edoxaban factsheet here
The National Institute for Health and Care Excellence (NICE) have issued a new atrial fibrillation quality standard, NICE quality standard 93.
The quality standard covers the treatment and management of atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (18 years and older). It will cover adults with both valvular and non-valvular atrial fibrillation.
Adults with atrial fibrillation (AF) should be prescribed newer medications instead of aspirin for the prevention of stroke, says NICE.
IMPORTANT: Statement on Device Malfunction
Following recent inaccurate media reports on supposedly faulty devices, the following statement is being issued jointly by Arrhythmia Alliance and British Heart Rhythm Society.
Sunday 4 October 2015 International Convention Centre (ICC), Birmingham
Thank you to everyone who attended and made Patients Day a big success.
Please take a moment to complete our feedback survey.
As a registered charity, AF Association relies solely on supporters in order to continue providing valuable helpline services, information and educational activities.
AF Association has launched an online petition which calls for an early review of the UK National Screening Committee’s (NSC) policy on screening for AF in the over 65s. Please sign our petition and together we can make a difference and help to prevent suffering. Read more.
EHRA Position Paper
Cardiac tachyarrhythmias are recurrent or chronic and in some cases life-threatening conditions. Heart rhythm disturbances are often highly symptomatic and the psychological impact of the disease can be significant.
An assessment of today’s challenges with recommendations for the future.
Healthcare Pioneers Report - April 2015
Showcasing best practice in AF. Supported by the All-Parliamentary Group on Atrial Fibrillation (APGAF).
The route map for change & the European atlas on the prevention of AF-related stroke – November 2014
Last November AF Association and Anticoagulation Europe launched a landmark report to raise awareness among policy makers of the growing burden posed by strokes due to atrial fibrillation.
Researchers at King’s College London are looking to recruit participants with persistent AF who are due to undergo cardioversion, catheter ablation or AV node ablation with pacemaker. If you would like to take part, or for more information, click here.